MedTrace Logo

3mg Liraglutide for Overweight or Obesity

NCT03885297 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2024-06-18

No results posted yet for this study

Summary

In this study investigators will investigate the beneficial metabolic sequelae of Liraglutide in patients with obesity or overweight; including changes in vital signs, anthropometric characteristics (weight, body mass index and body composition), biochemical parameters, metabolomics and micro-ribonucleotide acid (miRNA) molecules from blood tests. Liraglutide is a commercially available analogue of a gut hormone physiologically produced in our bowel in response to food, licenced for the treatment of overweight or obesity. Liraglutide will be offered to patients attending National Health System (NHS) or private clinics within indication and according to their agreed clinical management. Investigators aim to collect real-life information for this study along with planned clinical management from patients who agree to their treatment and to take part in our study. Patients will be able to withdraw from treatment and study at any time without giving any explanation.

If successful, this study will help us combine clinical, biochemical and molecular information which will allow us to gain deeper understanding on the mechanisms behind the beneficial metabolic effects of Liraglutide in overweight and obesity. Data generated from this study will hopefully help us acquire funding for a larger multicentre study; the results of which can have substantial impact on millions of people with overweight or obesity around the world.

Conditions

Interventions

DRUG

Saxenda

Obesity pharmacotherapy

OTHER

Lifestyle modification

Tier 3 NHS weight management

DIAGNOSTIC_TEST

Metabolomics

Small molecule intermediates and products of metabolism

DIAGNOSTIC_TEST

miRNA

Small non-coding RNA molecules

Sponsors & Collaborators

  • Kingston University

    collaborator OTHER

  • University of Warwick

    collaborator OTHER

  • University of Birmingham

    collaborator OTHER

  • University Hospitals Coventry and Warwickshire NHS Trust

    lead OTHER

Principal Investigators

  • Georgios K. Dimitriadis · University Hospitals Coventry and Warwickshire NHS Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-18
Primary Completion
2020-12-18
Completion
2020-12-18

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03885297 on ClinicalTrials.gov